Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Ethyleneglycolmonosalicylic Acid Ester
2. Glycol Monosalicylate
3. Glycol Salicylate
4. Hydroxyethyl Salicylate
5. Menthoneurin
1. 87-28-5
2. Glycol Salicylate
3. 2-hydroxyethyl 2-hydroxybenzoate
4. Ethylene Glycol Monosalicylate
5. Espirosal
6. Glycol Monosalicylate
7. Rheumacyl
8. Sarocol
9. Spirosal
10. Glysal
11. Ethylene Glycol Salicylate
12. Phlogont
13. Monoglycol Salicylate
14. Gl 7
15. Benzoic Acid, 2-hydroxy-, 2-hydroxyethyl Ester
16. Glykolsalicylat
17. Traumasenex
18. Ethylene Glycol, Salicylate
19. Kytta-gel
20. Ethylene Glycol, Monosalicylate
21. 1,2-ethylene Glycol Monosalicylate
22. Aethylenglykolsalicylat
23. Hydroxyethyl Salicylate
24. 2-hydroxybenzoic Acid 2-hydroxyethyl Ester
25. Salicylic Acid, 2-hydroxyethyl Ester
26. Ethylenglycol-monosalicylsaeureester
27. Nsc-72097
28. 3i1vbb7axh
29. .beta.-hydroxyethyl Salicylate
30. Chebi:86541
31. 2-hydroxyethyl 2-oxidanylbenzoate
32. Mfcd00002862
33. Ncgc00159379-03
34. 2-hydroxybenzoic Acid, 2-hydroxyethyl Ester
35. Glycol Salicylate (jan)
36. Glycol Salicylate [jan]
37. Unii-3i1vbb7axh
38. Norgesic (tn)
39. Phlogont (tn)
40. Einecs 201-737-2
41. Nsc 72097
42. Ai3-05033
43. 2-hydroxyethyl-salicylate
44. Bmse000750
45. Dsstox_cid_28913
46. Dsstox_rid_83181
47. Dsstox_gsid_48987
48. Schembl15402
49. Salicylic Acid Ethylene Glycol
50. Glycol Salicylate [mi]
51. Chembl173562
52. Dtxsid4048987
53. Glycol Salicylate [inci]
54. Lvylcbnxhhhpsb-uhfffaoysa-
55. Glycol Salicylate [mart.]
56. Glycol Salicylate [who-dd]
57. Cs-b1707
58. Hy-b2208
59. Nsc72097
60. Zinc1698306
61. Salicylic Acid 2-hydroxyethyl Ester
62. Tox21_113462
63. Akos009075810
64. Db11323
65. Cas-87-28-5
66. Ncgc00159379-02
67. Ncgc00159379-04
68. 2-hydroxy-benzoicacid2-hydroxyethyl Ester
69. Sy032913
70. E0113
71. Ft-0626298
72. Salicylic Acid, 2-hydroxyethyl Ester (8ci)
73. Hydroxyethyl Salicylate [ep Monograph]
74. D01557
75. E78954
76. Ethylene Glycol Monosalicylate, >=98.0% (gc)
77. A842078
78. Q117422
79. Sr-01000944719
80. Sr-01000944719-1
81. W-104034
82. Hydroxyethyl Salicylate, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 182.17 g/mol |
---|---|
Molecular Formula | C9H10O4 |
XLogP3 | 1.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 182.05790880 g/mol |
Monoisotopic Mass | 182.05790880 g/mol |
Topological Polar Surface Area | 66.8 Ų |
Heavy Atom Count | 13 |
Formal Charge | 0 |
Complexity | 169 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
This drug is only recommended for topical usages for the relief of muscular and rheumatic pain in human and animals.
Temporarily relieves minor to moderate aches and pains. Works with ingredients such as menthol, which has counter-irritant properties. Counter-irritants are externally applied, and lead to irritation or mild inflammation of the skin to relieve pain in muscles or joints by reducing inflammation in deeper adjacent structures. Counter-irritants relieve pain by disrupting the brain from receiving pain signals resulting from conditions such as osteoarthritis (OA) or injuries such as sprains or strains. These agents may cause vasodilatation or skin irritation, leading to a false sensation of heat or warmth.
Absorption
Salicylate absorption follows first-order kinetics with an absorption half-life ranging from 5 to 16 minutes.
Route of Elimination
Salicylates are generally excreted.
The metabolism of glycol salicylate is similar to that of [DB00945] at other salicylates. Metabolism of salicylic acid occurs through glucuronide formation (to produce salicyl acyl glucuronide and salicyl phenolic glucuronide), conjugation with glycine (to produce salicyluric acid), and oxidation to gentisic acid. The rate of formation of salicyl phenolic glucuronide and salicyluric acid are readily saturated at low salicylic acid concentrations and their formation is described by Michaelis-Menten kinetics. The larger the dose administered, the longer it will take to reach steady-state concentrations of salicylates. There is also evidence that enzyme induction of salicyluric acid formation occurs during the metabolism of salicylates.
The serum half-life of [DB00945], a similar salicylate, is 20 min.
Similar to other salicylates. Salicylates and other analgesics and anti-inflammatory drugs, particularly the non-steroidal anti-inflammatory drugs (NSAID) mainly used in rheumatology, inhibit cyclooxygenase, therefore reducing prostaglandin synthesis.
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
79
PharmaCompass offers a list of Hydroxyethyl Salicylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hydroxyethyl Salicylate manufacturer or Hydroxyethyl Salicylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hydroxyethyl Salicylate manufacturer or Hydroxyethyl Salicylate supplier.
PharmaCompass also assists you with knowing the Hydroxyethyl Salicylate API Price utilized in the formulation of products. Hydroxyethyl Salicylate API Price is not always fixed or binding as the Hydroxyethyl Salicylate Price is obtained through a variety of data sources. The Hydroxyethyl Salicylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DSSTox_CID_28913 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DSSTox_CID_28913, including repackagers and relabelers. The FDA regulates DSSTox_CID_28913 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DSSTox_CID_28913 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DSSTox_CID_28913 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DSSTox_CID_28913 supplier is an individual or a company that provides DSSTox_CID_28913 active pharmaceutical ingredient (API) or DSSTox_CID_28913 finished formulations upon request. The DSSTox_CID_28913 suppliers may include DSSTox_CID_28913 API manufacturers, exporters, distributors and traders.
click here to find a list of DSSTox_CID_28913 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DSSTox_CID_28913 CEP of the European Pharmacopoeia monograph is often referred to as a DSSTox_CID_28913 Certificate of Suitability (COS). The purpose of a DSSTox_CID_28913 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DSSTox_CID_28913 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DSSTox_CID_28913 to their clients by showing that a DSSTox_CID_28913 CEP has been issued for it. The manufacturer submits a DSSTox_CID_28913 CEP (COS) as part of the market authorization procedure, and it takes on the role of a DSSTox_CID_28913 CEP holder for the record. Additionally, the data presented in the DSSTox_CID_28913 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DSSTox_CID_28913 DMF.
A DSSTox_CID_28913 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DSSTox_CID_28913 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DSSTox_CID_28913 suppliers with CEP (COS) on PharmaCompass.
DSSTox_CID_28913 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DSSTox_CID_28913 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DSSTox_CID_28913 GMP manufacturer or DSSTox_CID_28913 GMP API supplier for your needs.
A DSSTox_CID_28913 CoA (Certificate of Analysis) is a formal document that attests to DSSTox_CID_28913's compliance with DSSTox_CID_28913 specifications and serves as a tool for batch-level quality control.
DSSTox_CID_28913 CoA mostly includes findings from lab analyses of a specific batch. For each DSSTox_CID_28913 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DSSTox_CID_28913 may be tested according to a variety of international standards, such as European Pharmacopoeia (DSSTox_CID_28913 EP), DSSTox_CID_28913 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DSSTox_CID_28913 USP).